Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets

v3.19.1
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2019
Jun. 30, 2018
Current assets:    
Cash $ 9,037 $ 15,934
Accounts receivable - trade 117 75
Prepaid expenses and other current assets 432 276
Total Current Assets 9,586 16,285
Fixed assets, net of accumulated depreciation 24,641 25,152
Intangible assets, net of accumulated amortization 1,423 1,620
Security deposits 24 26
Total Assets 35,674 43,083
Current liabilities:    
Accounts payable (related party of $74 and $189 as of March 31, 2019 and June 30, 2018, respectively) 722 790
Accrued expenses (related party of $764 and $789 as of March 31, 2019 and June 30, 2018, respectively) 1,074 1,048
Capital lease obligation – current portion 209 197
Contract liabilities 2,041 0
Total Current Liabilities 4,046 2,035
Capital lease obligation - net of current portion 24,726 24,884
Total Liabilities 28,772 26,919
Commitments and Contingencies
iBio, Inc. Stockholders' Equity:    
Common stock - $0.001 par value; 275,000,000 shares authorized; 19,602,458 and 16,040,126 shares issued and outstanding as of March 31, 2019 and June 30, 2018, respectively 20 16
Additional paid-in capital 108,236 104,408
Accumulated other comprehensive loss (31) (30)
Accumulated deficit (101,318) (88,228)
Total iBio, Inc. Stockholders' Equity 6,907 16,166
Noncontrolling interest (5) (2)
Total Equity 6,902 16,164
Total Liabilities and Equity 35,674 43,083
iBio CMO [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series A Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued 0 0
Series B Preferred Stock [Member]    
iBio, Inc. Stockholders' Equity:    
Preferred Stock, Value, Issued $ 0 $ 0